← Oncology Approval Tracker

FDA DECISION ·

Columvi

glofitamab-gxbm · Genentech

Accelerated approvalNew therapyLarge B-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory DLBCL not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma, after two or more systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

A fixed-duration bispecific regimen added an option after multiple prior therapies.

What research teams should watch

Verify lymphoma subtype and plan pretreatment, step-up infusions and cytokine release syndrome surveillance.

PRIMARY RECORDS

Sources